Friday, May 20, 2022
Arabic Arabic Bengali Bengali English English French French Hindi Hindi Indonesian Indonesian Malay Malay Punjabi Punjabi Russian Russian Spanish Spanish Turkish Turkish Urdu Urdu

Covid-19: India approves Cadila’s 3-dose needle-free vaccine – News

Must Read

defy: Defy Gravity Pro true wireless earbuds launched, priced at Rs 1,399

Imagine Marketing (Parent company of Boat) owned Defy has unveiled its new True wireless series called Gravity. Under...

Unfair to punish Pakistan for Imran Khan’s Russia visit: Bilawal Bhutto

Foreign Minister Bilawal Bhutto speaks to media at UN Headquarters. — Radio PakistanUNITED NATIONS: Foreign Minister Bilawal Bhutto-Zardari...



Cadila’s vaccine will be the second home-grown shot to get emergency approval in India.

The Indian drug regulator’s subject expert committee has recommended emergency use approval for Zydus Cadila’s three-dose Covid-19 vaccine, CNBC-TV18 reported on Friday, citing sources.

The committee added that Zydus needs to submit additional data for the 2-dose regimen of its vaccine, CNBC-TV18 said in a tweet.

The generic drugmaker, listed as Cadila Healthcare Ltd, applied for the authorisation of the vaccine ZyCoV-D on July 1, based on an efficacy rate of 66.6 per cent in a late-stage trial of more than 28,000 volunteers nationwide.

If approved, Zydus Cadila’s vaccine will be the second home-grown shot to get emergency authorisation in India after Bharat Biotech’s Covaxin.

Zydus Cadila and India’s drug regulator did not immediately respond to a Reuters request for comment.




- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -